AzTrials
AzTrials

Pleural EffusionNCT04683419

Modified Thoracoscopic Pleural Cryobiopsy in Diagnosis of Exudative Pleural Effusion

A study testing Modified Thoracoscopic pleural Cryobiopsy in people with Pleural Effusion, run by Alexandria University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background: Rigid thoracoscopy is the gold standard tool for diagnosing exudative pleural effusion but sometimes it is difficult to obtain sufficient biopsies using the conventional forceps. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pleural Effusion
What is being tested?
Modified Thoracoscopic pleural Cryobiopsy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteEgypt
Study dates
11 Nov 2020to 15 Jan 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patient with undiagnosed exudative pleural effusion

Who cannot join

  • Any contraindications to medical thoracoscopy like:
  • Inability to tolerate lateral decubitus position Unstable cardiovascular or hemodynamic status Presence of severe, uncorrectable hypoxemia despite oxygen therapy Bleeding diathesis Refractory cough Drug Hypersensitivity Reduced general health status with short suspected survival
  • Refusal to participate

Trial locations and contacts

1 site in 1 country.

Egypt1 site, 1 recruiting
  • Chest Department, Alexandria Faculty of Medicine

    Alexandria

    Ayman I Baess, PhD, 1006822068 ext. +20, ayman.baeis@alexmed.edu.eg

    Recruiting

Other trials in Egypt

About this study

Official title: Modified Thoracoscopic Pleural Cryobiopsy in Diagnosis of Exudative Pleural Effusion of Undetermined Etiology

Background: Rigid thoracoscopy is the gold standard tool for diagnosing exudative pleural effusion but sometimes it is difficult to obtain sufficient biopsies using the conventional forceps.

Objectives: This study evaluated the efficacy, safety and diagnostic value of a modified technique using cryoprobe to obtain pleural biopsies during thoracoscopy.

Methods: This is a single center prospective study in patients who will undergo rigid thoracoscopy using conventional rigid forceps followed by a cryoprobe from the same site after injection of subpleural mixture of adrenaline and xylocaine. Biopsies will be reviewed by an independent pathologist; any complications will be recorded, and all patients will be followed up post procedure.

Read the detailed description

Brief Summary: Background: Rigid thoracoscopy is the gold standard tool for diagnosing exudative pleural effusion but sometimes it is difficult to obtain sufficient biopsies using the conventional forceps..

Objectives: This study evaluated the efficacy, safety and diagnostic value of a modified technique using cryoprobe to obtain pleural biopsies during thoracoscopy.

Methods: This is a single center prospective study in patients who will undergo rigid thoracoscopy using conventional rigid forceps followed by a cryoprobe from the same site after injection of subpleural mixture of adrenaline and xylocaine. Biopsies will be reviewed by an independent pathologist and any complications will be recorded.

Detailed Description: The present study will prospectively enroll 24 patients with undiagnosed exudate pleural effusion who are admitted to Alexandria Main University Hospital , chest department .

All patients will undergo thoracoscopy whom biopsies will be taken using the modified cryo-biopsy technique and the conventional forceps biopsy technique.

All included patients will be subjected to :

  • Full history .
  • Clinical examination .
  • Routine laboratory investigations including complete blood picture, prothrombin activity and international normalized ratio (INR).
  • Radiological evaluation including:
  • Plain x-ray poster-anterior view,
  • Computed topography scan of the chest
  • Ultrasound examination of the pleural cavity.
  • Thoracentesis and pleural fluid analysis will be done including:
  • Microbiological examination.
  • Biochemical examination (Protein-Glucose-LDH).
  • Cytopathological examination.
  • Follow up chest x-ray will be done .

Thoracoscopy:

  1. Endoscopy suite:

The endoscopy suite contains :

  1. Thoracoscopy table: with a back that can be raised .
  2. A separate sterile table for placing the thoracoscope, trocar, forceps and other accessories.
  3. Adjustable aspiration equipment for the pleural fluid (BMI VAC60).
  4. Simple anesthetic equipment with nasal prongs and central oxygen.
  5. Mayo stand placed sideways across the thoracoscopy table to hold the instruments.
  6. Electrocautery unit (ERBE ICC 200 EA, Germany).
  7. Electrical systems which are attached to a voltage regulator and auxiliary electrical supply independent of the mains.
  8. An included area for handwashing and area for sterilization of instruments.
  9. Mobile carts for light sources and video camera.
  10. Ultrasonography device (Philips ClearVue 350, Mexico)
  11. Electronic medical records including Desktop computer, TV-Box (AV Grabber PRO WS-VR203P), and LCD screen (LG 32") .

II. Sterile conditions:

III. Patient monitoring during the procedure:

IV. Personnel:

The main personnel will be; a physician , an assistant operator , an assistant nurse, a circulating nurse outside the sterile field and a medical worker

  1. Equipment:
  2. Thoracoscope:

Rigid thoracoscope: (Karl Storz GmbH \& Co., Germany) will be used .

Instruments for rigid thoracoscopy included:

  • A metallic trocar with multifunctional valve with insufflation stopcock, 11mm in diameter and autoclavable.
  • A 10 mm straight forward telescope 0º with angled eyepiece with a 6 mm working channel (26038AA, K. Storz-Endoskope, Tuttlingen, Germany)
  1. Forceps:

Rotational biopsy forceps with connector pin for uni-polar coagulation will be used. They are 5 mm in diameter.

  1. Cryo-Equipment:

The cryo-equipment consists of a cylinder containing cryogen stored under high pressure, a console (cryo-machine) that controls the flow of cryogen and a catheter with a cryoprobe at one end to freeze target tissue.The thoracoscopist will use a foot pedal to regulate the flow of the cryogen through the catheter from the cylinder to the cryoprobe. The cryo-machine available is ERBOCRYO CA, Tubingen, Germany.

  1. Flexible Cryoprobe:

A flexible cryoprobe with a diameter of 2.4 mm was used to collect the pleura by firmly attaching it to the biopsy site for (10 - 30seconds) (ERBE, technikGmBH, Tubingen, Germany).

  1. Rigid Cryoprobe:

A rigid cryoprobe will be used and the same steps were adopted as in case of using flexible Cryoprobe(ERBE, technikGmBH, Tubingen, Germany).

  1. Transbronchial Needle:

A trans-bronchial needle with 1.8 mm diameter will be used to inject subpleural mixture of lidocaine 2%and epinephrine diluted by normal saline 9% to facilitate pleural biopsy using cryo technique (Aspiration needle ENDO-FLEX, Voerde, Germany).

VI. Phases of medical thoracoscopy :

  1. Patient positioning:

The patient lay on the healthy side with the diseased side up , the arm will be raised over the head and a pillow will be placed on the table under the patient's flank to widen the targeted intercostal spaces.

  1. Selecting the point of entry:

The point of entry will be determined near the mid-axillary line within the axillary triangle (bounded anteriorly by the inferior edge of pectoralis major muscle, posteriorly by the anterior edge of the latissimus dorsi muscle, cranially by the axillary apex and caudally down to the level of diaphragmatic insertion). The point of entry will be usually determined by ultrasonography and most commonly it is in the fifth, sixth or seventh intercostal spaces.

  1. Anaesthesia:

Medical thoracoscopy in the current study will be done under local anaesthesia with moderate sedation . In some cases, general anesthesia will be applied if patients refuse local anesthesia and moderate sedation.

For local anaesthesia, the following steps will be done:

  • The previously marked site of entry will be palpated with the index and middle fingers of one hand .
  • Between the two fingers, a syringe (small bore, 27 gauge) will be filled with 1ml of 2% lidocaine (Debocaine®) will be used for intradermal injection to produce a small bleb.
  • The local anaesthetic (10-15 ml of 2% lidocaine) in a larger bore syringe will infiltrate subcutaneously and in the intercostal muscles down to the parietal pleura.
  • The path of the needle will be perpendicular to the chest wall ensuring that the needle has not penetrated a vascular structure.

At the location of the parietal pleural, about 8-10 ml of lidocaine will be infiltrated.The caudal rim of the upper rib will be infiltrated to anaesthetize the intercostal nerve as well as the periosteum of the rib itself then a further lidocaine depot of about 8-10 ml will be then injected around the cranial rim of the lower rib.

  1. Performance of rigid thoracoscopy will be done using rigid scopes through single-port technique.

Steps performed:

  • A 10-15 mm horizontal incision will be made at the pre-determined point of entry , parallel to and in the middle of the selected intercostal spaces
  • Blunt dissection will be performed through the subcutaneous space, the intercostal muscles and the parietal pleura using a haemostat .
  • Once the parietal pleura is opened, the index finger will be introduced through this opening to examine the pleura.
  • The trocar is held with its head in the operator's palm and the extended index finger on its shaft in a position that limited the depth of insertion for safety's sake.
  • The movement of air in and out of the pleural space should be heard during patient's respiration. Furthermore, pressure equilibrium with the atmosphere is established .
  • The trocar will be removed, leaving the cannula in place then the pleural fluid will be aspirated by a suction catheter.
  • The rigid scope will be then introduced through the cannula to gain access to the inside of the pleura.
  • The pleural space will be visualized by the thoracoscope video-transmission.
  • After removal of the pleural fluid, a systematic exploration of the chest cavity will be performed.
  • In case of fine adhesions , mechanical separation will be possibly done using the forceps or the scope itself.
  • In case of vascular adhesions or thick fibrous bands, electrocautery forceps will be used.

Biopsy techniques: thoracoscopic pleural biopsies are usually taken from the suspected parietal pleural lesions using the rigid forceps. They are taken against a rib to minimize the risk of vessel or nerve injury. Those biopsies will be taken using single-port single-instrument rigid technique .

Two techniques for the rigid forceps will be applied in the current study, first "punch biopsy" technique and second "strip biopsy" technique where the parietal pleura is grasped and gently pulled toward the operator then pulled sideways and in shearing motion, a "strip" of pleura could be isolated. In certain occasions, large "several centimeters long" specimens may be obtained .

Five to ten biopsies of suspicious pleural lesions will be taken. In cases of suspected malignancy , 10-12 parietal pleural biopsies from different locations will be taken.

Another biopsy technique will then be applied after subpleural injection of the diluted mixture of epinephrine and lidocaine 2% using transbronchial needle till subpleural raising and bleb is formed, then introduction of the cryoprobe (either the flexible or the rigid ) to be attached to the biopsy site then the operator uses the cryo-machine pedal for delivering the freezing effect through the cryoprobe for at least (10 - 30) seconds then grasping the cryoprobe with the attached pleural biopsy will be done, The tissue attached to the tip of the cryoprobe will be spontaneously thawed in normal saline at room temperature, three to five biopsies of suspicious pleural lesions were taken.

No biopsies will be taken from the anterior costoparietal pleura for fear of bleeding secondary to injury of the internal mammary artery .

Chest tube insertion:

The chest tube will be connected to a thoracic drainage device. chest x-ray will be then performed, and the patient will be discharged and scheduled for follow-up. Days till chest tube removal will be calculated and recorded.

VII. The follow-up of patients:

Follow up will be done following the procedure to detect any complications till discharge of the patient.

Follow-up will be carried out by chest x-ray.

VIII. Grading for Fat cells and crushed cells:

the measurement of the quantity of fat cells and crushed cells will be done as follows , if there will be no presence was marked as negative and if less than 5% of the biopsy will be marked as + and if 5-25% of the biopsy will be marked as ++ and if more than 25% it will take +++ in both limbs of the cryo and forceps techniques.

IX. Post-procedure complications Post-procedure complications will be recorded with the followings;

  1. Local site ''wound'' infection.
  2. Pneumothorax/ incomplete lung expansion.
  3. Fever
  4. Pain
  5. Bleeding.
Being tested
Modified Thoracoscopic pleural Cryobiopsy
Keywords
Thoracoscopy, Cryobiopsy
Medical subject headings
Pleural Effusion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Modified Thoracoscopic pleural CryobiopsyDevice

    Thoracoscopic pleural biopsy will be taken with a modified technique "raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"

Study groups in NCT04683419
Study groupRoleWhat they receive
Patients with pleural effusion of Undetermined etiologyExperimentalPatients with undiagnosed exudative pleural effusion will undergo modified pleural cryobiopsies and conventional pleural forceps biopsies in the same settings
Receives: Device: Modified Thoracoscopic pleural Cryobiopsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison between pleural biopsy specimens obtained by modified cryoprobe technique and conventional rigid forceps during medical thoracoscopy in diagnosis of pleural effusion regarding size of the obtained pleural biopsies.

    Size of the pleural biopsies obtained by both procedures will be compared in millimeters

    Measured: Immediately after ending the procedure

  2. Comparison between pleural biopsy specimens obtained by modified cryoprobe technique and conventional rigid forceps during medical thoracoscopy in diagnosis of pleural effusion regarding depth of the obtained pleural biopsies.

    Depth of the pleural biopsies obtained by both procedures will be compared by "grading of fat cells" Grading will be as follows: if there will be no presence of fat cells, this will be marked as negative and if less than 5% of the biopsy will be marked as + and if 5-25% of the biopsy will be marked as ++ and if more than 25% it will take +++ in both limbs of the cryo and forceps techniques.

    Measured: 1 week

  3. Comparison between pleural biopsy specimens obtained by modified cryoprobe technique and conventional rigid forceps during medical thoracoscopy in diagnosis of pleural effusion regarding integrity of the obtained pleural biopsies.

    Integrity of the pleural biopsies obtained by both procedures will be compared by percentage of "crushed cells."" Grading will be as follows: if there will be no presence of crushed cells, this will be marked as negative and if less than 5% of the biopsy will be marked as + and if 5-25% of the biopsy will be marked as ++ and if more than 25% it will take +++ in both limbs of the cryo and forceps techniques.

    Measured: 1 week

Secondary outcomes (1)
  1. Safety of the procedure of thoracoscopic pleural biopsies

    Recording of any complications during the period of hospital stay.

    Measured: During the period of hospital stay

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2020
  2. Study start11 Nov 2020
  3. Primary completion10 Jan 2021 (estimated)
  4. Study completion15 Jan 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04683419
Sponsor's protocol ID
0105678
Status last verified
Dec 2020
First submitted
5 Dec 2020
Last updated
24 Dec 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data should be confirmed in larger, multi-sites studies.

Questions about this trial

What is this clinical trial studying?

A study testing Modified Thoracoscopic pleural Cryobiopsy in people with Pleural Effusion, run by Alexandria University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ayman I Baess, PhD (1006822068 ext. +20, ayman.baeis@alexmed.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison between pleural biopsy specimens obtained by modified cryoprobe technique and conventional rigid forceps during medical thoracoscopy in diagnosis of pleural effusion regarding size of the obtained pleural biopsies. (time frame: Immediately after ending the procedure). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in